Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
View ORCID ProfileVincent Auvigne, View ORCID ProfileCynthia Tamandjou, View ORCID ProfileJustine Schaeffer, View ORCID ProfileSophie Vaux, Isabelle Parent du Chatelet
doi: https://doi.org/10.1101/2023.03.17.23287411
Vincent Auvigne
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Cynthia Tamandjou
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Justine Schaeffer
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Sophie Vaux
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
Isabelle Parent du Chatelet
1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France

- Supplementary material[supplements/287411_file02.pdf]
Posted March 18, 2023.
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Subject Area
Subject Areas
- Addiction Medicine (280)
- Allergy and Immunology (579)
- Anesthesia (139)
- Cardiovascular Medicine (1946)
- Dermatology (184)
- Emergency Medicine (333)
- Epidemiology (11102)
- Gastroenterology (624)
- Genetic and Genomic Medicine (3168)
- Geriatric Medicine (308)
- Health Economics (561)
- Health Informatics (2042)
- Health Policy (863)
- Hematology (310)
- HIV/AIDS (682)
- Medical Education (317)
- Medical Ethics (92)
- Nephrology (334)
- Neurology (2986)
- Nursing (164)
- Nutrition (463)
- Oncology (1552)
- Ophthalmology (477)
- Orthopedics (185)
- Otolaryngology (266)
- Pain Medicine (202)
- Palliative Medicine (57)
- Pathology (403)
- Pediatrics (912)
- Primary Care Research (355)
- Public and Global Health (5591)
- Radiology and Imaging (1093)
- Respiratory Medicine (759)
- Rheumatology (338)
- Sports Medicine (289)
- Surgery (343)
- Toxicology (48)
- Transplantation (159)
- Urology (132)